Pharming Group NV
PHARM:AEXActions
Health CarePharmaceuticals & Biotechnology
PRICE (EUR)
0.317
TODAY'S CHANGE
0.003 / 0.96%
SHARES TRADED
2.76m
1 YEAR CHANGE
47.86%
BETA
-0.6821
Data delayed at least 15 minutes, as of May 02 2017 13:20 BST.
Summary
Charts
Profile
Directors & dealings
Financials
Forecasts
Consensus recommendation
As of Apr 28, 2017, the consensus forecast amongst 3 polled investment analysts covering Pharming Group N.V. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Jul 30, 2015. The previous consensus forecast advised investors to hold their position in Pharming Group N.V..
Previous recommendations
1yr ago
3M ago
2M ago
1M ago
Latest
Select bar for recommendation details.
Recommendations 1yr ago Latest
Buy
1 1
Outperform
2 2
Hold
1 0
Underperform
0 0
Sell
0 0
Share price forecast
The 3 analysts offering 12 month price targets for Pharming Group N.V. have a median target of 1.20, with a high estimate of 1.30 and a low estimate of 0.66. The median estimate represents a 282.17% increase from the last price of 0.314.
Past 12 months
Next 12 months
1.0
0.5
1.5
High
314.0% 1.30
Med
282.2% 1.20
Low
110.2% 0.66
Earnings history & estimates
On Mar 09, 2017, Pharming Group N.V. reported semi annual 2016 losses of -0.016 per share.
Forecasts
2015H1
2015H2
2016H1
2016H2
2017Q1
2017Q2
0
0
0
Average growth rate +9.37%
Pharming Group N.V. reported annual 2016 losses of -0.042 per share on Mar 09, 2017.
Forecasts
2013
2014
2015
2016
2017
2018
0
0
0
Average growth rate -73.92%
Revenue history & estimates
Pharming Group N.V. reported semi annual 2016 revenues of 10.60m. This was 89.50% above the prior year's period results.
Forecasts
2017Q1
2017Q2
10m
20m
Average growth rate --
Pharming Group N.V. had revenues for the full year 2016 of 15.87m. This was 46.59% above the prior year's results.
Forecasts
2013
2014
2015
2016
2017
2018
50m
100m
Average growth rate +42.94%
FT Lexicon
Lexicon on this page
betaoutperformrevenueunderperform
Go to FT Lexicon
Explore our tools
Alerts
Data archive
Portfolio
World markets
Equities screener
Funds overview
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Welcome to the FT.com Markets Data
We’re constantly improving and would like to hear from you.
Provide Feedback